Viral Clearance

Sep 01, 2018
BioPharm International
Viral vaccines and viral vectors used in biotherapeutic applications carry the risk of microbial contamination, which must be addressed.
Jun 28, 2018
By BioPharm International Editors
The new resin used a combination of “jetting” technology and a high-performance Protein A ligand.
May 01, 2018
BioPharm International
Process understanding and careful assessment of risks are essential in developing viral clearance programs.
Oct 01, 2017
BioPharm International
This study outlines methods for an alternative protein-polishing process for challenging proteins.
Oct 01, 2017
BioPharm International
Detecting viral contaminants in biologic-based medicines—and identifying their source—requires a holistic testing approach.
Sep 15, 2017
BioPharm International
A case study demonstrates that affinity chromatography can offer efficiency and scalability for gene therapy manufacturing using viral vectors.
Sep 01, 2017
BioPharm International
Protecting against microbiological contamination over the whole manufacturing process grows increasingly important.
Jul 01, 2017
BioPharm International
Continuous processing of 100 g of monoclonal antibody in 24 hours has been demonstrated using lab-scale equipment.
Jun 01, 2017
BioPharm International
Increased understanding of potential impurities has spurred efforts to standardize monitoring procedures.
May 01, 2017
BioPharm International
The unique structures of fusion proteins lead to expression, heterogeneity, and stability issues.
native1_300x100
lorem ipsum